investor relations

Introduction

Cube’s best-in-class science team has identified an array of psilocybin and psilocin brain receptors solutions that can be applied to our team’s industry-leading and pre-existing Neurobiology Patents. We see this as a competitive advantage to fast-track Cube’s psilocybin and psilocin research and development plan to develop evolving life sciences of psilocybin and psilocin drugs for clinical trials and patient prescribed uses. Cubes sciences team will be based out of the company's state-of-the-art GMP-certified facility located in Ontario, Canada.

By executing rapid expansion plans, Cube will generate near-term growth & cash flow. By building a well-balanced and multi-disciplined team, Cube can leverage its Neurobiology Patents and sector-specific expertise and will allow the Company to provide shareholders extraordinary rates of returns based on a platform of long-term growth, stability, and profitability.

Investor Deck PDF Invest Now

Introduction

Investor Deck PDF

Investor Highlights

positioned to capitalize on powerful market trends

Cube Psytech Corporation. is a Canadian bio-pharmaceutical and biotechnology company positioned to capitalize on powerful market trends in psilocybin to improve health issues such as mental illness, PTSD, addiction disorders, cancer, and depression. The company was founded in January 2021. The company is comprised of a best-in-class science and executive leadership team with access to patents and capitals markets experience. The team has proven track records of starting up and growing new Health Canada regulated businesses that are focused on controlled substances.

World class drug delivery and formulation R&D Science Team
Accessibility for 10+ patents on precision drug delivery systems.
Access for 1902 total publications on psychedelics of 1239 psilocybin to date.
Expedited CSE and OTC Markets Dual Listing Go Public Plan.
Proven Capital Markets Experiences.
Land and Building Assets.
Functional Mushroom Supplement Line launching 1st quarter 2022.

Patents Accessibility for Innovative Technologies

Neurobiology Patents that can be used further using Psilocybin and Psilocin molecules for brain

receptors:

1. Biomarker for diagnosing toxicity of nanoparticles and method for evaluating toxicity of nanoparticles using the same. (United States patent and Trademark Office (USPTO), Co-inventor; Patent number: 9689019, Date of Patent: June 27, 2017).

2. Nano-neurotoxicity bio-marker composition based on intracellular aggregates which are biomarkers of degenerative brain diseases (United States patent and Trademark Office (USPTO), Co-inventor; Patent number: 20190194715, Date of Patent: June 27, 2019).

Controlled environment and grow condition Patents – in Plants but it can be modified to any

eukaryotic organisms (Fungus/Mycelium):

1. Effect of intensity and wavelength of red, blue, amber lights on quality and quantity of lettuce plants (United States patent and Trademark Office (USPTO), Co-inventor).

2. Light effect on enhancing the quality and quantity of lettuce ((United States patent and Trademark Office (USPTO), Inventor.

150 Species

Available genetic species globally – Psilocybin related

Button
$34B Globally By 2025

Forecast To $34 Billion
Globally By 2025.
Button
6% Annual Growth Rate

The Global Functional
Mushroom Market Is Growing
Button

$18B MARKET SHARE GLOBALLY

45%

Percentage of Canadians
experiencing a major
depressive episode that
do not receive “potentially
adequate care”
Button
#4

Canada’s rank in the use
of antidepressant drugs
per capita. The use of
antidepressants is on the rise
globally.
Button
27 Patents

1958-2020
Psilocybin Related Patents

Button

We Own Our Own Land.

Cube Psytech Land & Facilities

One of the first things we did as a company was buy 3.5 acres of land in Southern Ontario. Our total facility expansion will comprise of over 45,000 sq/ft cultivation, processing, manufacturing and distribution of psylocibin.

Facility Phases

1

Phase 1

4,000 sqft for R&D

2

Phase 2

15,000 sqft for Functional Mushrooms

3

Phase 3

27,000 sqft for EU GMP Facility

Button
Button

Explore More: Cube Psytech Land & Facilities

In February of 2021, Cube Psytech purchased 3.5 acres of land with an existing 4,000 sq/ft industrial building that was an affordable retrofit for our R&D exemption licence application with Health Canada. We have an approved site plan application to build two additional structures on our property. Building 2 will be 15,000 sq/ft purpose-built cultivation and processing facility. Building 3 will be a 27,000 sq/ft Health Canada approved facility for psychedelic mushrooms. The facility will be used to grow, process, research & develop functional and future mushroom products. The total cost of our 2nd building is estimated to be approximately $2 million dollars to completion. All of our facilities are designed to be cGMP certified, Health Canada Compliant and FDA registered.

Cube Psytech anticipates that the project will advance quickly. Ramara’s planning department has already approved the preliminary construction design for the initial portion of the facility. Detailed plans for the first 4,000 sq-ft R&D facility have been submitted and approved by Ramara’s building department. Cube has assembled an in-house team of compliance experts that have successfully obtained multiple licences with Health Canada. Cube has submitted complete license application for research and development of psylocibin with Health Canada.

Our Products

NATURAL FUNCTIONAL MUSHROOMS Products

Our world-class team of doctors, formulators, and scientists have developed 5 purpose-focused products that are nonpsychoactive, and address 5 modern ailments health issues. Our product line focuses on solutions to anxiety / stress, mental clarity, immune support, energy and mental / physical recovery.

Simply put - Our products work. Strenuous testing in the development phase and proven ingredients are utilized in all of our formulas. Our products carry the following Certifications – All Natural, FDA Complaint, Certified Organic, Non-GMO, DrugFree, Vegan, Gluten and Allergen Free and Non-Habit forming.